Novartis is developing the site into a life science park
The Basel pharmaceutical company Novartis is planning to expand its production site in Stein to become the Rheintal Life Science Park. He wants to send a positive signal for Switzerland as an industrial center and the Aargau region.
The biotechnology and pharmaceutical company Novartis has announced plans to open its production site in Stein and locate more life science companies there. According to a press release, the Rheintal Life Science Park is to be built there.
"Switzerland is an important location for our production network," is how Steffen Lang, head of Novartis Technical Operations and member of the group management, is quoted. Investments of more than CHF 200 million in 2020 and 2021 at the Stein and Schweizerhalle locations confirmed Novartis' commitment to the region. "With the further development of the Stein location into the Rheintal Life Science Park, we are sending a positive signal for Switzerland as an industrial center and the Aargau region."
The location offers an ideal environment, access to highly qualified employees from the region and state-of-the-art facilities, for example for the production of cell and gene therapies.
The Novartis plans are also approved by the cantonal location promotion agency Aargau Services . After all, according to its director Annelise Alig Anderhalden, “the whole Sisslerfeld” is an “important place of work and a focus of development for the canton. The area has great potential for businesses with high added value. "